Clinician's Roundtable

Genetic studies have shown that changes in the gene for APRIL are associated with an increased risk of developing IgA nephropathy. So what should clinicians know about the ARPIL pathway? Dive in with Dr. Jonathan Barratt, The Mayer Professor of Renal Medicine at the University of Leicester in the United Kingdom.

A new class of drugs are looking at the ability to reduce proteinuria and protect the loss of kidney function. So what do clinicians need to know about the treatment landscape for IgA nephropathy? Tune in with Dr. Jonathan Barratt, The Mayer Professor of Renal Medicine at the University of Leicester in the United Kingdom.

IgA nephropathy has a few aspects to it that make it challenging to develop medications, particularly, focused medications. So what are the challenges or limitations associated with the therapies? Join Dr. Charles Turck as he discusses this in-depth with Dr. Pietro Canetta, Associate Professor of Medicine at Columbia University Irving Medical Center.

Dr. Canetta did not receive compensation for this interview.

From this clinician’s perspective, we should be testing any and all patients for COPD. So how could this help us overcome barriers for these patients? Join Dr. Charles Turck as he speaks with Dr. Brian Smith, specializes in Family Medicine and Hospice and Palliative Medicine at Versailles Family Medicine in Kentucky.

Click here to order free AlphaID™ screening kits to rule out Alpha-1 deficiency in your patients.

From this clinician’s perspective, we should be testing any and all patients for COPD. So how could this help us overcome barriers for these patients? Join Dr. Charles Turck as he speaks with Dr. Brian Smith, specializes in Family Medicine and Hospice and Palliative Medicine at Versailles Family Medicine in Kentucky.

To Order Free AlphaID™ Screening Kits to Rule Out Alpha-1: https://www.alphaid.com/en/hcp/home

Early intervention is key when it comes to optimizing outcomes among patients suffering from malnutrition. Explore best practices for identifying and treating adult malnutrition with Dr. Charles Turck and Dr. Dejan Micic, Associate Professor of Medicine at UChicago Medicine.

Discover best practices for taking a collaborative, multidisciplinary approach to nutritional care with Dr. Dawn Adams, Medical Director for the Center for Human Nutrition at Vanderbilt University Medical Center.

The available treatment options and even the current guidelines for the management of IgA nephropathy (IgAN) come with several limitations. Fortunately, new therapies are on the horizon that can help us address those challenges and slow disease progression in IgAN. Here with Dr. Charles Turck to discuss limitations and advances in the IgAN treatment landscape is Dr. Pietro Canetta, Associate Professor of Medicine at Columbia University Medical Center in New York.

Commercially blenderized and standard tube feeding formulas are both ways we can deliver food to our patients requiring home enteral nutrition. So how do these two types of formulas stack up against one another? Find out with Dr. Charles Turck as he discusses the latest literature findings and other key considerations with Dr. Carolyn Newberry, Director of GI Nutrition at Weill Cornell Medical Center’s Division of Gastroenterology.

There are several key markers of disease progression in IgA nephropathy (IgAN) that we should be aware of, and the biochemical pathways involving endothelin-1 (ET-1) and angiotensin II (Ang II) play an important role in driving that progression. Joining Dr. Charles Turck to shed light on these two pathways and how our knowledge of ET-1 and Ang II may impact the treatment landscape is Dr. Rajeev Raghavan, Program Director for HCA Kingwood Internal Medicine in Texas.